Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study

BACKGROUND: Familial non-medullary thyroid cancer (NMTC) are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. OBJECTIVES: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafiei, Susan, Sadrolodabaei, Mehrdokht, Aghaei, Atena, Ayati, Narjess, Zare Namdar, Samira, Hemati, Donya, Zakavi, Seyed Rasoul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198615/
https://www.ncbi.nlm.nih.gov/pubmed/34149846
http://dx.doi.org/10.5812/ijem.108781
_version_ 1783707181321814016
author Shafiei, Susan
Sadrolodabaei, Mehrdokht
Aghaei, Atena
Ayati, Narjess
Zare Namdar, Samira
Hemati, Donya
Zakavi, Seyed Rasoul
author_facet Shafiei, Susan
Sadrolodabaei, Mehrdokht
Aghaei, Atena
Ayati, Narjess
Zare Namdar, Samira
Hemati, Donya
Zakavi, Seyed Rasoul
author_sort Shafiei, Susan
collection PubMed
description BACKGROUND: Familial non-medullary thyroid cancer (NMTC) are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. OBJECTIVES: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. METHODS: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. RESULTS: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. CONCLUSIONS: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative.
format Online
Article
Text
id pubmed-8198615
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-81986152021-06-18 Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study Shafiei, Susan Sadrolodabaei, Mehrdokht Aghaei, Atena Ayati, Narjess Zare Namdar, Samira Hemati, Donya Zakavi, Seyed Rasoul Int J Endocrinol Metab Research Article BACKGROUND: Familial non-medullary thyroid cancer (NMTC) are supposed to be more aggressive and require more frequent treatment compared to non-familial thyroid cancer. OBJECTIVES: This matched case-control study aimed to compare the response to treatment between the matched case-control groups of familial and sporadic NMTC. METHODS: This is a retrospective study in patients with familial NMTC (at least one other first-degree relative involved) who were treated with surgery, followed by radio-iodine therapy (RIT) without consideration of its familial origin. Response to treatment was compared between familial NMTC and age, sex, and TNM stage-matched non-familial NMTC (control group). Response to treatment was assessed one and two years after RIT, and time to excellent response was identified. RESULTS: Out of 2,944 NMTC patients, 81 (2.75%) patients had familial NMTC. We compared 66 patients with familial NMTC and 66 sporadic NMTC patients. There was no significant difference in first thyroglobulin, initial and accumulative iodine dose, and additional treatments (additional surgery and radiotherapy) between patients and controls. Although no significant difference was noted in one and two years’ responses to treatment between the case and control groups, familial NMTC patients required more time to achieve excellent response (26.7 ± 24.9 versus 15.9 ± 9.0 months, P = 0.01). No significant difference was noted between familial NMTC patients with two or more than two involved relatives. CONCLUSIONS: Our study showed that if patients with familial NMTCs were treated in the same way as non-familial patients, the time to excellent response would be significantly longer, even when they have only one other involved relative. Kowsar 2021-05-11 /pmc/articles/PMC8198615/ /pubmed/34149846 http://dx.doi.org/10.5812/ijem.108781 Text en Copyright © 2021, International Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Shafiei, Susan
Sadrolodabaei, Mehrdokht
Aghaei, Atena
Ayati, Narjess
Zare Namdar, Samira
Hemati, Donya
Zakavi, Seyed Rasoul
Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title_full Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title_fullStr Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title_full_unstemmed Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title_short Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study
title_sort longer time to reach excellent response to treatment in familial versus sporadic non-medullary thyroid cancer (nmtc): a matched case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198615/
https://www.ncbi.nlm.nih.gov/pubmed/34149846
http://dx.doi.org/10.5812/ijem.108781
work_keys_str_mv AT shafieisusan longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT sadrolodabaeimehrdokht longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT aghaeiatena longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT ayatinarjess longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT zarenamdarsamira longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT hematidonya longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy
AT zakaviseyedrasoul longertimetoreachexcellentresponsetotreatmentinfamilialversussporadicnonmedullarythyroidcancernmtcamatchedcasecontrolstudy